Since miRNA has been reported to outperform AFP for HCC diagnosis 6-8, circulating microRNA is one of the emerging liquid biopsy technologies to complement AFP for HCC screening and prognosis 7-9. The gene discussed is AFP; the disease is hepatocellular carcinoma.